Morepen Labs Q1 FY25 profit surges 147% to Rs. 36.17 Cr

Morepen Labs successfully raised Rs. 200 Crore through QIP

Wockhardt Q1 FY25 revenue up 14%

EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year

Metropolis Healthcare posts Q1 FY25 at Rs. 38.1 Cr

Revenue from operations stood at Rs. 313.4 crore during Q1 FY25

Dr Reddys Laboratories posts Q1 FY25 consolidated PAT at Rs. 1,392 Cr

Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024

Syngene reports drop in Q1 FY25 revenue to Rs. 790 Cr

Reported profit after tax declined 19% year-on-year to Rs 76 crores

Industry hails Union Budget 2024-25

The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable

Rusan Pharma’s API plant in Ankleshwar receives USFDA GMP approval

Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well

7th India-Japan medical product regulatory symposium held at New Delhi

Enhanced collaboration under the Memorandum of Cooperation (MoC) between India and Japan in medical product regulations

Shilpa's CDMO customer placed binding purchase order

Briefs: Alembic Pharmaceuticals and Relonchem

Alembic Pharmaceuticals receives 11 USFDA product approval during Q1 FY2025